lopinavir Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
HIV protease inhibitors	1601	192725-17-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: lopinavir aluviran koletra	An HIV protease inhibitor used in a fixed-dose combination with RITONAVIR. It is also an inhibitor of CYTOCHROME P-450 CYP3A. There was some evidence of in vitro activity against SARS-CoV-2, but no clinical trial data was found to support use in the treatment of COVID-19. Molecular weight: 628.81 Formula: C37H48N4O5 CLOGP: 6.09 LIPINSKI: 2 HAC: 9 HDO: 4 TPSA: 120 ALOGS: -5.51 ROTB: 15 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

lopinavir
aluviran
koletra

An HIV protease inhibitor used in a fixed-dose combination with RITONAVIR. It is also an inhibitor of CYTOCHROME P-450 CYP3A. There was some evidence of in vitro activity against SARS-CoV-2, but no clinical trial data was found to support use in the treatment of COVID-19.

Molecular weight: 628.81
Formula: C37H48N4O5
CLOGP: 6.09
LIPINSKI: 2
HAC: 9
HDO: 4
TPSA: 120
ALOGS: -5.51
ROTB: 15

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.80	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	2.20 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	24.22 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

Date	Agency	Company	Orphan
Sept. 15, 2000	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Exposure during pregnancy	1210.98	23.46	605	13223	124255	53210983
Abortion spontaneous	720.90	23.46	313	13515	46322	53288916
Off label use	581.72	23.46	658	13170	471554	52863684
Foetal exposure during pregnancy	522.97	23.46	229	13599	34486	53300752
Stillbirth	479.39	23.46	141	13687	6656	53328582
Abortion induced	414.79	23.46	141	13687	10685	53324553
Virologic failure	338.78	23.46	85	13743	2179	53333059
Viral mutation identified	331.03	23.46	82	13746	1992	53333246
Drug interaction	264.77	23.46	304	13524	219025	53116213
Foetal death	263.66	23.46	97	13731	9250	53325988
Maternal exposure during pregnancy	259.07	23.46	256	13572	155383	53179855
Premature baby	248.15	23.46	115	13713	19686	53315552
Immune reconstitution inflammatory syndrome	224.86	23.46	78	13750	6268	53328970
Drug resistance	219.64	23.46	106	13722	19856	53315382
Hypomania	200.37	23.46	67	13761	4815	53330423
Jaundice cholestatic	199.86	23.46	69	13759	5465	53329773
Live birth	193.45	23.46	89	13739	14970	53320268
Hepatotoxicity	162.42	23.46	97	13731	27783	53307455
Premature rupture of membranes	160.76	23.46	57	13771	4883	53330355
Pregnancy	159.18	23.46	100	13728	31341	53303897
Schizophrenia	155.11	23.46	68	13760	10211	53325027
Premature labour	152.34	23.46	71	13757	12291	53322947
Caesarean section	138.04	23.46	74	13754	17246	53317992
Blood HIV RNA increased	134.35	23.46	33	13795	772	53334466
Pathogen resistance	127.65	23.46	52	13776	6508	53328730
Fanconi syndrome acquired	119.93	23.46	32	13796	1049	53334189
Blood bilirubin increased	119.62	23.46	88	13740	35642	53299596
Viral load increased	114.54	23.46	33	13795	1442	53333796
HIV infection	112.78	23.46	27	13801	565	53334673
Premature delivery	112.35	23.46	75	13753	26029	53309209
Psychotic disorder	109.64	23.46	72	13756	24313	53310925
Ergot poisoning	107.93	23.46	22	13806	210	53335028
Treatment noncompliance	107.52	23.46	80	13748	32955	53302283
Lipodystrophy acquired	102.25	23.46	31	13797	1619	53333619
CD4 lymphocytes decreased	97.08	23.46	30	13798	1671	53333567
Skull malformation	87.63	23.46	20	13808	337	53334901
COVID-19 pneumonia	87.58	23.46	41	13787	7162	53328076
Spina bifida	81.39	23.46	22	13806	758	53334480
Long QT syndrome	77.65	23.46	30	13798	3266	53331972
Pain	77.62	23.46	28	13800	588370	52746868
Cholelithiasis	74.66	23.46	71	13757	40893	53294345
Human immunodeficiency virus transmission	68.80	23.46	13	13815	80	53335158
Fatigue	68.27	23.46	54	13774	730452	52604786
Genotype drug resistance test positive	68.17	23.46	18	13810	566	53334672
Electrocardiogram QT prolonged	67.36	23.46	78	13750	56325	53278913
COVID-19	67.34	23.46	64	13764	36824	53298414
Foetal growth restriction	66.70	23.46	34	13794	7140	53328098
Immunosuppressant drug level increased	65.89	23.46	27	13801	3428	53331810
Trisomy 21	64.50	23.46	16	13812	390	53334848
Normal newborn	60.93	23.46	32	13796	7147	53328091
Cushing's syndrome	59.06	23.46	17	13811	740	53334498
Cerebral ventricle dilatation	57.96	23.46	18	13810	1019	53334219
Portal hypertension	57.32	23.46	25	13803	3703	53331535
Hyperbilirubinaemia	55.45	23.46	35	13793	11034	53324204
Eosinophilia	54.93	23.46	45	13783	21290	53313948
Fall	54.57	23.46	13	13815	358427	52976811
Pre-eclampsia	52.71	23.46	31	13797	8616	53326622
Dyspnoea	49.03	23.46	48	13780	586184	52749054
Drug ineffective	46.21	23.46	89	13739	817156	52518082
Hepatocellular injury	45.41	23.46	47	13781	29939	53305299
Placental disorder	43.56	23.46	16	13812	1515	53333723
Patent ductus arteriosus	42.65	23.46	21	13807	4097	53331141
Hepatic cytolysis	42.19	23.46	26	13802	7859	53327379
Rash maculo-papular	42.14	23.46	45	13783	29704	53305534
Arnold-Chiari malformation	41.87	23.46	12	13816	514	53334724
Rickets	41.45	23.46	8	13820	56	53335182
Alopecia	41.02	23.46	6	13822	234577	53100661
Renal tubular dysfunction	40.47	23.46	11	13817	387	53334851
Renal tubular disorder	40.15	23.46	18	13810	2845	53332393
Vomiting	39.84	23.46	242	13586	496897	52838341
Hepatic enzyme increased	38.08	23.46	94	13734	126101	53209137
Placenta praevia	37.98	23.46	13	13815	1001	53334237
Arthralgia	37.89	23.46	35	13793	439748	52895490
Acquired immunodeficiency syndrome	37.27	23.46	8	13820	100	53335138
Peripheral swelling	36.66	23.46	5	13823	206103	53129135
Coarctation of the aorta	36.23	23.46	11	13817	577	53334661
Neural tube defect	36.22	23.46	9	13819	221	53335017
Anticoagulation drug level increased	36.10	23.46	9	13819	224	53335014
Urinary tract infection	35.89	23.46	9	13819	239894	53095344
Polydactyly	35.65	23.46	10	13818	396	53334842
Swelling	35.54	23.46	4	13824	191101	53144137
Gene mutation	35.00	23.46	13	13815	1270	53333968
Placental insufficiency	34.11	23.46	13	13815	1363	53333875
Pulmonary tuberculosis	33.75	23.46	19	13809	4862	53330376
Product dose omission issue	33.26	23.46	5	13823	191615	53143623
Ventricular septal defect	33.00	23.46	18	13810	4332	53330906
Mitochondrial cytopathy	32.70	23.46	9	13819	332	53334906
Atrial septal defect	32.49	23.46	21	13807	6893	53328345
Congenital anomaly	32.07	23.46	13	13815	1604	53333634
Gestational diabetes	31.95	23.46	22	13806	8017	53327221
Brachydactyly	31.62	23.46	7	13821	102	53335136
Anaemia	31.14	23.46	148	13680	276570	53058668
Dysmorphism	31.09	23.46	14	13814	2236	53333002
Renal tubular acidosis	31.07	23.46	13	13815	1738	53333500
Nephropathy toxic	30.68	23.46	22	13806	8550	53326688
Drug reaction with eosinophilia and systemic symptoms	30.48	23.46	40	13788	32760	53302478
Oligohydramnios	29.90	23.46	19	13809	6057	53329181
Cardiac malposition	29.55	23.46	6	13822	56	53335182
Hypertriglyceridaemia	29.26	23.46	19	13809	6285	53328953
Maternal drugs affecting foetus	28.94	23.46	18	13810	5528	53329710
Cerebral toxoplasmosis	28.79	23.46	10	13818	805	53334433
Constipation	28.61	23.46	8	13820	198404	53136834
Cholestasis of pregnancy	28.46	23.46	11	13817	1198	53334040
Transaminases increased	28.39	23.46	37	13791	30095	53305143
Pregnancy on contraceptive	28.11	23.46	11	13817	1238	53334000
Foetal malformation	28.09	23.46	7	13821	174	53335064
Hypophosphataemia	27.90	23.46	21	13807	8784	53326454
Pain in extremity	27.86	23.46	20	13808	285030	53050208
Hepatic displacement	26.86	23.46	5	13823	28	53335210
Congenital eye disorder	26.29	23.46	5	13823	32	53335206
Spinocerebellar disorder	25.90	23.46	5	13823	35	53335203
Hyperlactacidaemia	25.58	23.46	13	13815	2712	53332526
Mental disability	25.51	23.46	6	13822	116	53335122
Drug hypersensitivity	25.41	23.46	19	13809	265223	53070015
Benign hydatidiform mole	24.77	23.46	6	13822	132	53335106
Twin pregnancy	24.63	23.46	10	13818	1239	53333999
Threatened labour	24.28	23.46	9	13819	874	53334364
Therapeutic response unexpected	24.24	23.46	26	13802	17244	53317994
Meningitis cryptococcal	24.16	23.46	10	13818	1301	53333937
Dizziness	24.15	23.46	37	13791	372222	52963016
COVID-19 treatment	24.12	23.46	6	13822	148	53335090
Acute respiratory distress syndrome	24.11	23.46	30	13798	23302	53311936
Meningomyelocele	24.03	23.46	8	13820	566	53334672
Coronavirus infection	23.84	23.46	13	13815	3127	53332111
Abdominal discomfort	23.64	23.46	14	13814	221048	53114190

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Off label use	1311.47	15.01	1392	24301	304928	32182905
Drug interaction	1192.77	15.01	1134	24559	217051	32270782
Depression	693.55	15.01	589	25104	96471	32391362
Lipodystrophy acquired	595.07	15.01	187	25506	3495	32484338
Mitochondrial toxicity	443.45	15.01	138	25555	2492	32485341
Foetal exposure during pregnancy	366.49	15.01	285	25408	41016	32446817
Eyelid ptosis	332.54	15.01	135	25558	5407	32482426
Immune reconstitution inflammatory syndrome	253.48	15.01	132	25561	9427	32478406
Long QT syndrome	228.92	15.01	84	25609	2547	32485286
Progressive external ophthalmoplegia	225.68	15.01	70	25623	1248	32486585
Hypertransaminasaemia	221.00	15.01	93	25600	4081	32483752
Virologic failure	209.30	15.01	87	25606	3700	32484133
Diplopia	199.82	15.01	131	25562	14381	32473452
Hypertriglyceridaemia	190.82	15.01	106	25587	8613	32479220
Exposure during pregnancy	187.88	15.01	107	25586	9122	32478711
Fanconi syndrome acquired	178.60	15.01	67	25626	2163	32485670
Premature baby	158.00	15.01	125	25568	18393	32469440
Drug-induced liver injury	150.85	15.01	136	25557	23927	32463906
Hepatic fibrosis	144.12	15.01	66	25627	3552	32484281
Viral mutation identified	142.43	15.01	62	25631	2957	32484876
Electrocardiogram QT prolonged	140.83	15.01	165	25528	39476	32448357
Loss of personal independence in daily activities	138.21	15.01	136	25557	26697	32461136
COVID-19	118.28	15.01	136	25557	31879	32455954
Drug effective for unapproved indication	107.16	15.01	41	25652	1398	32486435
Fanconi syndrome	97.83	15.01	41	25652	1779	32486054
Hyperbilirubinaemia	97.16	15.01	93	25600	17637	32470196
Renal tubular disorder	97.04	15.01	57	25636	5145	32482688
Pathogen resistance	96.04	15.01	71	25622	9439	32478394
HIV infection	95.59	15.01	41	25652	1885	32485948
Kaposi's sarcoma	93.99	15.01	34	25659	988	32486845
Viral load increased	93.62	15.01	47	25646	3103	32484730
Death	92.46	15.01	100	25593	382417	32105416
Trisomy 21	89.69	15.01	28	25665	510	32487323
Osteoporosis	84.60	15.01	73	25620	12109	32475724
Nephropathy toxic	83.80	15.01	72	25621	11874	32475959
Drug ineffective	76.33	15.01	116	25577	383361	32104472
COVID-19 pneumonia	72.50	15.01	58	25635	8662	32479171
Ophthalmoplegia	69.09	15.01	30	25663	1421	32486412
Volvulus	67.86	15.01	29	25664	1321	32486512
Drug resistance	64.49	15.01	85	25608	22880	32464953
Drug level increased	63.75	15.01	79	25614	20001	32467832
Extraocular muscle paresis	61.18	15.01	21	25672	521	32487312
Hyperlactacidaemia	60.82	15.01	35	25658	3039	32484794
Fatigue	60.62	15.01	116	25577	350585	32137248
Hepatocellular injury	58.05	15.01	85	25608	25233	32462600
Fall	57.14	15.01	43	25650	196158	32291675
Congenital anomaly	57.03	15.01	26	25667	1384	32486449
Febrile neutropenia	55.83	15.01	13	25680	119553	32368280
Cushing's syndrome	52.84	15.01	18	25675	436	32487397
Product dose omission issue	52.38	15.01	9	25684	102566	32385267
CD4 lymphocytes decreased	51.69	15.01	28	25665	2162	32485671
Acquired immunodeficiency syndrome	50.93	15.01	18	25675	488	32487345
Dyslipidaemia	49.32	15.01	42	25651	6841	32480992
Hyperlipidaemia	49.16	15.01	59	25634	14452	32473381
Osteoporotic fracture	48.34	15.01	22	25671	1166	32486667
Dyspnoea	47.92	15.01	138	25555	361907	32125926
Glycosuria	47.63	15.01	23	25670	1395	32486438
HIV-associated neurocognitive disorder	47.35	15.01	16	25677	378	32487455
Hypotension	47.21	15.01	61	25632	216049	32271784
Pneumonia	44.42	15.01	139	25554	355113	32132720
Mitochondrial cytopathy	43.27	15.01	13	25680	207	32487626
Osteonecrosis	42.81	15.01	59	25634	16563	32471270
Lipoatrophy	42.73	15.01	17	25676	644	32487189
Portal hypertension	42.51	15.01	31	25662	4033	32483800
Peripheral swelling	42.39	15.01	3	25690	68342	32419491
Proteinuria	42.31	15.01	60	25633	17295	32470538
Immunosuppressant drug level increased	42.29	15.01	34	25659	5111	32482722
Malignant neoplasm progression	42.08	15.01	6	25687	78490	32409343
Hypophosphataemia	42.02	15.01	43	25650	8832	32479001
Hepatic failure	41.57	15.01	89	25604	35591	32452242
Polydactyly	41.23	15.01	20	25673	1225	32486608
HIV associated nephropathy	40.20	15.01	14	25679	363	32487470
Cardiac failure congestive	40.04	15.01	9	25684	84843	32402990
Osteomalacia	39.89	15.01	18	25675	935	32486898
Liver injury	39.36	15.01	52	25641	14022	32473811
Coronavirus infection	38.12	15.01	28	25665	3684	32484149
Constipation	37.65	15.01	27	25666	126346	32361487
Hepatosplenomegaly	36.86	15.01	28	25665	3875	32483958
Cerebral toxoplasmosis	36.83	15.01	20	25673	1552	32486281
Blood triglycerides increased	36.32	15.01	51	25642	14568	32473265
CD4 lymphocytes increased	36.14	15.01	12	25681	268	32487565
Ventricular septal defect	35.59	15.01	27	25666	3730	32484103
Pain	35.02	15.01	59	25634	187497	32300336
Blood lactic acid increased	34.49	15.01	33	25660	6248	32481585
Blood pressure increased	34.40	15.01	10	25683	79344	32408489
Hepatic cytolysis	33.47	15.01	37	25656	8296	32479537
Hepatitis	33.43	15.01	64	25629	23629	32464204
Completed suicide	32.86	15.01	16	25677	92501	32395332
Muscle spasms	32.17	15.01	8	25685	70410	32417423
Portal fibrosis	31.78	15.01	12	25681	394	32487439
Gastroschisis	31.57	15.01	9	25684	118	32487715
Hyperferritinaemia	31.47	15.01	12	25681	405	32487428
Disease progression	30.88	15.01	15	25678	86847	32400986
Adrenogenital syndrome	30.79	15.01	8	25685	72	32487761
Low set ears	30.69	15.01	12	25681	434	32487399
Lipohypertrophy	30.49	15.01	11	25682	317	32487516
Cryptorchism	30.42	15.01	19	25674	1915	32485918
Blood bilirubin increased	29.40	15.01	82	25611	38702	32449131
Product use in unapproved indication	28.96	15.01	141	25552	87063	32400770
Atypical mycobacterial infection	28.73	15.01	14	25679	866	32486967
Maternal drugs affecting foetus	28.42	15.01	25	25668	4252	32483581
Cholestasis	27.62	15.01	64	25629	26969	32460864
Acute kidney injury	27.50	15.01	353	25340	293115	32194718
Bronchopulmonary aspergillosis	27.18	15.01	43	25650	13644	32474189
Liver disorder	27.09	15.01	70	25623	31584	32456249
Multiple-drug resistance	26.97	15.01	23	25670	3752	32484081
Anal cancer	26.94	15.01	11	25682	446	32487387
Urinary tract infection	26.73	15.01	15	25678	80056	32407777
Neonatal asphyxia	26.70	15.01	10	25683	321	32487512
Live birth	26.38	15.01	9	25684	219	32487614
Epistaxis	26.19	15.01	6	25687	55849	32431984
Oesophageal candidiasis	25.79	15.01	24	25669	4390	32483443
Inappropriate schedule of product administration	25.76	15.01	3	25690	45822	32442011
Taeniasis	25.76	15.01	7	25686	76	32487757
Drug ineffective for unapproved indication	25.31	15.01	42	25651	13870	32473963
Renal failure	25.08	15.01	187	25506	134291	32353542
Urticaria	24.95	15.01	8	25685	59606	32428227
Acute respiratory distress syndrome	24.94	15.01	59	25634	25194	32462639
Exomphalos	24.78	15.01	8	25685	163	32487670
Syphilis	24.01	15.01	11	25682	592	32487241
Congenital hearing disorder	23.68	15.01	7	25686	105	32487728
Kidney malformation	23.67	15.01	8	25685	189	32487644
HIV wasting syndrome	23.62	15.01	7	25686	106	32487727
Stillbirth	23.44	15.01	8	25685	195	32487638
Antiviral drug level above therapeutic	23.09	15.01	6	25687	54	32487779
Jaundice	22.79	15.01	69	25624	34089	32453744
Back pain	22.54	15.01	33	25660	111020	32376813
Oesophageal atresia	22.50	15.01	10	25683	501	32487332
Dizziness	22.10	15.01	88	25605	209530	32278303
Cortisol decreased	22.01	15.01	12	25681	938	32486895
Speech sound disorder	21.90	15.01	7	25686	138	32487695
Pneumocystis jirovecii pneumonia	21.89	15.01	47	25646	18823	32469010
Adrenal suppression	21.81	15.01	11	25682	733	32487100
Drug abuse	21.55	15.01	19	25674	80224	32407609
Splenomegaly	21.53	15.01	40	25653	14437	32473396
Mycobacterium avium complex infection	21.30	15.01	18	25675	2899	32484934
Eosinophilia	21.15	15.01	55	25638	24903	32462930
Endotracheal intubation	21.07	15.01	17	25676	2568	32485265
Transaminases increased	21.06	15.01	55	25638	24973	32462860
Somnolence	20.91	15.01	31	25662	103766	32384067
Small for dates baby	20.89	15.01	19	25674	3374	32484459
Feeling abnormal	20.63	15.01	11	25682	60412	32427421
Hepatic function abnormal	20.62	15.01	80	25613	44760	32443073
Cushingoid	20.56	15.01	17	25676	2657	32485176
Infection	20.50	15.01	22	25671	84693	32403140
Gamma-glutamyltransferase increased	20.36	15.01	62	25631	30720	32457113
Lymphadenopathy	20.26	15.01	57	25636	27025	32460808
Haemoglobin decreased	20.21	15.01	40	25653	119631	32368202
Renal tubular acidosis	20.13	15.01	15	25678	2017	32485816
COVID-19 treatment	20.11	15.01	8	25685	303	32487530
Burkitt's lymphoma	20.08	15.01	7	25686	182	32487651
Normal newborn	20.01	15.01	7	25686	184	32487649
Joint swelling	19.85	15.01	8	25685	51727	32436106
Lactic acidosis	19.85	15.01	65	25628	33471	32454362
Castleman's disease	19.77	15.01	5	25688	40	32487793
Rhabdomyolysis	19.69	15.01	105	25588	67160	32420673
Hepatic cirrhosis	19.65	15.01	42	25651	16767	32471066
Erythema	19.65	15.01	22	25671	83083	32404750
Porphyria non-acute	19.33	15.01	9	25684	503	32487330
ADAMTS13 activity decreased	19.23	15.01	6	25687	109	32487724
Faeces pale	19.10	15.01	13	25680	1516	32486317
Andersen-Tawil syndrome	19.04	15.01	4	25689	12	32487821
Mixed liver injury	19.01	15.01	16	25677	2564	32485269
Hyperreflexia	18.85	15.01	17	25676	2987	32484846
Therapeutic response unexpected	18.81	15.01	30	25663	9582	32478251
Blood alkaline phosphatase increased	18.77	15.01	62	25631	32070	32455763
Death neonatal	18.70	15.01	8	25685	365	32487468
Musculoskeletal toxicity	18.60	15.01	6	25687	122	32487711
Viral load decreased	18.59	15.01	5	25688	52	32487781
Neutrophil count decreased	18.57	15.01	7	25686	47132	32440701
Candida infection	18.52	15.01	41	25652	16762	32471071
Renal impairment	18.34	15.01	130	25563	91842	32395991
Low birth weight baby	18.27	15.01	25	25668	6969	32480864
Hepatomegaly	18.26	15.01	31	25662	10426	32477407
Protrusion tongue	18.25	15.01	7	25686	240	32487593
Foetal growth restriction	18.20	15.01	19	25674	3993	32483840
Pain in extremity	18.19	15.01	42	25651	118859	32368974
Encephalitis	18.13	15.01	25	25668	7019	32480814
Blood phosphorus decreased	18.08	15.01	17	25676	3149	32484684
Cytomegalovirus chorioretinitis	18.01	15.01	18	25675	3594	32484239
Cachexia	17.95	15.01	25	25668	7084	32480749
Psoriasis	17.92	15.01	7	25686	46116	32441717
Hepatotoxicity	17.83	15.01	44	25649	19293	32468540
Drug hypersensitivity	17.83	15.01	19	25674	73381	32414452
Pneumococcal infection	17.63	15.01	8	25685	421	32487412
Sickle cell disease	17.47	15.01	6	25687	149	32487684
Cellulitis	17.36	15.01	9	25684	50221	32437612
Loss of consciousness	17.35	15.01	24	25669	82683	32405150
Chest pain	17.31	15.01	46	25647	124091	32363742
Caesarean section	17.29	15.01	14	25679	2125	32485708
Wheezing	17.21	15.01	4	25689	36870	32450963
Anxiety	17.16	15.01	31	25662	95974	32391859
Arthralgia	17.14	15.01	60	25633	148388	32339445
Nephropathy	16.98	15.01	22	25671	5818	32482015
Prenatal screening test abnormal	16.96	15.01	4	25689	23	32487810
Hepatitis toxic	16.79	15.01	14	25679	2214	32485619
Delayed graft function	16.77	15.01	13	25680	1854	32485979
Cerebral ventricle dilatation	16.71	15.01	10	25683	933	32486900
Red blood cell schistocytes present	16.63	15.01	7	25686	307	32487526
Hospitalisation	16.59	15.01	9	25684	48962	32438871
Hepatitis cholestatic	16.55	15.01	26	25667	8199	32479634
Congenital abdominal hernia	16.54	15.01	4	25689	26	32487807
Therapeutic product effect incomplete	16.52	15.01	6	25687	41335	32446498
Blood pressure decreased	16.43	15.01	10	25683	51070	32436763
Confusional state	16.42	15.01	58	25635	143057	32344776
Ergot poisoning	16.39	15.01	5	25688	84	32487749
Acute hepatitis C	16.37	15.01	6	25687	181	32487652
Immunoblastic lymphoma	16.36	15.01	3	25690	3	32487830
Progressive multifocal leukoencephalopathy	16.31	15.01	28	25665	9503	32478330
Influenza	16.27	15.01	8	25685	46006	32441827
Cerebrovascular accident	16.22	15.01	27	25666	86293	32401540
Transient tachypnoea of the newborn	16.22	15.01	6	25687	186	32487647
Syncope	16.20	15.01	29	25664	90095	32397738
Pancreatitis acute	16.19	15.01	53	25640	27282	32460551
Anticoagulation drug level increased	16.03	15.01	8	25685	521	32487312
Dysmorphism	15.96	15.01	15	25678	2778	32485055
Chest discomfort	15.92	15.01	10	25683	50220	32437613
Opportunistic infection	15.90	15.01	12	25681	1645	32486188
Renal tubular necrosis	15.42	15.01	37	25656	15941	32471892
Visceral leishmaniasis	15.40	15.01	8	25685	567	32487266
Mitochondrial myopathy	15.19	15.01	6	25687	223	32487610
Oral candidiasis	15.16	15.01	31	25662	11996	32475837
Aspartate aminotransferase increased	15.09	15.01	97	25596	66332	32421501
Bilirubin conjugated increased	15.01	15.01	16	25677	3442	32484391

Pharmacologic Action:

Source	Code	Description
ATC	J05AR10	ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Antivirals for treatment of HIV infections, combinations
FDA MoA	N0000000246	HIV Protease Inhibitors
FDA EPC	N0000175889	Protease Inhibitor
FDA MoA	N0000185503	P-Glycoprotein Inhibitors
FDA MoA	N0000190107	Organic Anion Transporting Polypeptide 1B1 Inhibitors
FDA MoA	N0000190114	Cytochrome P450 3A Inhibitors
CHEBI has role	CHEBI:35660	HIV protease inhibitors
CHEBI has role	CHEBI:36044	anti-virus drug
CHEBI has role	CHEBI:149553	anti-coronaviral agents
MeSH PA	D019380	Anti-HIV Agents
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D044966	Anti-Retroviral Agents
MeSH PA	D000998	Antiviral Agents
MeSH PA	D065692	Cytochrome P-450 CYP3A Inhibitors
MeSH PA	D065607	Cytochrome P-450 Enzyme Inhibitors
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D017320	HIV Protease Inhibitors
MeSH PA	D065606	Metabolic Side Effects of Drugs and Substances
MeSH PA	D011480	Protease Inhibitors
MeSH PA	D000084762	Viral Protease Inhibitors

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Human immunodeficiency virus infection	indication	86406008	DOID:526
Coronavirus infection	off-label use	186747009
Prevention of HIV Infection after Exposure	off-label use
Hyperbilirubinemia	contraindication	14783006	DOID:2741
Cirrhosis of liver	contraindication	19943007	DOID:5082
Complete atrioventricular block	contraindication	27885002
Hereditary factor VIII deficiency disease	contraindication	28293008	DOID:12134
Torsades de pointes	contraindication	31722008
Hereditary factor IX deficiency disease	contraindication	41788008	DOID:12259
Hypokalemia	contraindication	43339004
Conduction disorder of the heart	contraindication	44808001
Chronic type B viral hepatitis	contraindication	61977001
Diabetes mellitus	contraindication	73211009	DOID:9351
Hyperglycemia	contraindication	80394007	DOID:4195
Cardiomyopathy	contraindication	85898001	DOID:0050700
Prolonged QT interval	contraindication	111975006
Chronic hepatitis C	contraindication	128302006
Structural disorder of heart	contraindication	128599005
Liver function tests abnormal	contraindication	166603001
Hypomagnesemia	contraindication	190855004
Second degree atrioventricular block	contraindication	195042002
Acute pancreatitis	contraindication	197456007	DOID:2913
Disease of liver	contraindication	235856003	DOID:409
Mixed hyperlipidemia	contraindication	267434003
Hypertriglyceridemia	contraindication	302870006
Breastfeeding (mother)	contraindication	413712001
Myocardial ischemia	contraindication	414795007	DOID:3393
Congenital long QT syndrome	contraindication	442917000
First Degree Atrioventricular Heart Block	contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	12.03	acidic
pKa2	12.72	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Multidrug resistance protein 1	Transporter	P08183	MDR1_HUMAN		IC50	4.99	CHEMBL
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN		IC50	5.07	CHEMBL
Pol polyprotein	Enzyme		Q72874_9HIV1	INHIBITOR	Ki	10.40	CHEMBL	CHEMBL
Gag-Pol polyprotein	Polyprotein		POL_HV1BR				WOMBAT-PK
CAAX prenyl protease 1 homolog	Enzyme		FACE1_MOUSE		IC50	4.74	CHEMBL
Protease	Enzyme		Q9YQ12_9HIV1		IC50	7.60	CHEMBL
Protease	Unclassified		O90781_9PLVG		Ki	10.59	CHEMBL
Protease	Unclassified		Q9YQ30_9PLVG		Ki	10.54	CHEMBL

External reference:

ID	Source
4021228	VUID
N0000179581	NUI
D01425	KEGG_DRUG
4021228	VANDF
C0674432	UMLSCUI
CHEBI:31781	CHEBI
AB1	PDB_CHEM_ID
CHEMBL729	ChEMBL_ID
D061466	MESH_DESCRIPTOR_UI
DB01601	DRUGBANK_ID
11504	IUPHAR_LIGAND_ID
7798	INN_ID
2494G1JF75	UNII
92727	PUBCHEM_CID
195088	RXNORM
15774	MMSL
d04716	MMSL
008874	NDDF
129475001	SNOMEDCT_US
387067003	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Kaletra	HUMAN PRESCRIPTION DRUG LABEL	2	0074-0522	TABLET, FILM COATED	100 mg	ORAL	NDA	32 sections
Kaletra	HUMAN PRESCRIPTION DRUG LABEL	2	0074-1575	TABLET, FILM COATED	100 mg	ORAL	NDA	32 sections
Kaletra	HUMAN PRESCRIPTION DRUG LABEL	2	0074-2605	TABLET, FILM COATED	200 mg	ORAL	NDA	32 sections
Kaletra	HUMAN PRESCRIPTION DRUG LABEL	2	0074-3956	SOLUTION	80 mg	ORAL	NDA	32 sections
Kaletra	HUMAN PRESCRIPTION DRUG LABEL	2	0074-6799	TABLET, FILM COATED	200 mg	ORAL	NDA	32 sections
Lopinavir-Ritonavir	HUMAN PRESCRIPTION DRUG LABEL	2	0527-1947	SOLUTION	80 mg	ORAL	ANDA	27 sections
Kaletra	HUMAN PRESCRIPTION DRUG LABEL	2	11819-342	TABLET, FILM COATED	200 mg	ORAL	NDA	27 sections
Kaletra	HUMAN PRESCRIPTION DRUG LABEL	2	21695-362	TABLET, FILM COATED	200 mg	ORAL	NDA	27 sections
Lopinavir and ritonavir	HUMAN PRESCRIPTION DRUG LABEL	2	31722-556	TABLET, FILM COATED	200 mg	ORAL	ANDA	27 sections
Lopinavir and ritonavir	HUMAN PRESCRIPTION DRUG LABEL	2	31722-603	TABLET, FILM COATED	100 mg	ORAL	ANDA	27 sections
Kaletra	HUMAN PRESCRIPTION DRUG LABEL	2	53808-0276	TABLET, FILM COATED	200 mg	ORAL	NDA	27 sections
Kaletra	HUMAN PRESCRIPTION DRUG LABEL	2	54868-5566	TABLET, FILM COATED	200 mg	ORAL	NDA	27 sections
Kaletra	HUMAN PRESCRIPTION DRUG LABEL	2	55289-947	TABLET, FILM COATED	200 mg	ORAL	NDA	27 sections
Lopinavir and Ritonavir	HUMAN PRESCRIPTION DRUG LABEL	2	65015-299	GRANULE	40 mg	ORAL	Export only	1 sections
Kaletra	HUMAN PRESCRIPTION DRUG LABEL	2	66336-624	TABLET, FILM COATED	200 mg	ORAL	NDA	27 sections
Kaletra	HUMAN PRESCRIPTION DRUG LABEL	2	68071-2348	TABLET, FILM COATED	200 mg	ORAL	NDA	25 sections
Kaletra	HUMAN PRESCRIPTION DRUG LABEL	2	68258-1972	TABLET, FILM COATED	200 mg	ORAL	NDA	27 sections
Kaletra	HUMAN PRESCRIPTION DRUG LABEL	2	70518-0091	TABLET, FILM COATED	200 mg	ORAL	NDA	26 sections